Bicyclo Ring System Having The Four-membered Hetero Ring As One Of The Cyclos Patents (Class 514/210.04)
  • Patent number: 9447078
    Abstract: The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are substituted heterocyclic amine derivative compound and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.
    Type: Grant
    Filed: January 18, 2013
    Date of Patent: September 20, 2016
    Assignee: ACUCELA INC.
    Inventors: Vladimir A. Kuksa, Mark W. Orme, Feng Hong, Ryo Kubota
  • Patent number: 9040508
    Abstract: The present invention relates to novel synthetic substituted heterocyclic compounds and pharmaceutical compositions containing the same that are capable of inhibiting or antagonizing a family of receptor tyrosine kinases, Tropomysosin Related Kinases (Trk), in particular the nerve growth factor (NGF) receptor, TrkA. The invention further concerns the use of such compounds in the treatment and/or prevention of pain, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, or a disease, disorder or injury relating to dysmyelination or demyelination or the disease or disorder associated with abnormal activities of NGF receptor TrkA.
    Type: Grant
    Filed: December 8, 2009
    Date of Patent: May 26, 2015
    Assignee: VM Pharma LLC
    Inventors: Jay Jie-Qiang Wu, Ling Wang
  • Patent number: 8956653
    Abstract: The present invention relates to a process for preparing effervescent dosage forms comprising at least one antibiotic of cephalosporin group. The present invention also relates to effervescent formulations and preparations comprising antibiotics of second generation cephalosporin.
    Type: Grant
    Filed: July 30, 2012
    Date of Patent: February 17, 2015
    Inventor: Mahmut Bilgic
  • Patent number: 8445476
    Abstract: Carbacephem ?-lactam antibiotics having the following chemical structures (I) and (II) are disclosed: including stereoisomers, pharmaceutically acceptable salts, esters and prodrugs thereof, wherein Ar2, R1, R2 and R3 are as defined herein. The compounds are useful for the treatment of bacterial infections, in particular those caused by methicillin-resistant Staphylococcus spp.
    Type: Grant
    Filed: April 21, 2010
    Date of Patent: May 21, 2013
    Assignee: Achaogen, Inc.
    Inventors: Allan S. Wagman, Heinz E. Moser
  • Publication number: 20110301133
    Abstract: The present invention relates to novel synthetic substituted heterocyclic compounds and pharmaceutical compositions containing the same that are capable of inhibiting or antagonizing a family of receptor tyrosine kinases, Tropomysosin Related Kinases (Trk), in particular the nerve growth factor (NGF) receptor, TrkA. The invention further concerns the use of such compounds in the treatment and/or prevention of pain, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, or a disease, disorder or injury relating to dysmyelination or demyelination or the disease or disorder associated with abnormal activities of NGF receptor TrkA.
    Type: Application
    Filed: December 8, 2009
    Publication date: December 8, 2011
    Applicant: VM Pharma LLC
    Inventors: Jay Jie-Qiang Wu, Ling Wang
  • Publication number: 20110301127
    Abstract: The instant methods and compositions represent an advance in controlling drug resistance in microbes. AcrAB-like efflux pumps have been found to control resistance to drugs, even in highly resistant microbes. Accordingly, methods of treating infection, methods of screening for inhibitors of AcrAB-like efflux pumps, and methods of enhancing antimicrobial activity of drugs are provided. Pharmaceutical composition comprising an inhibitor of an AcrAB-like efflux pump and an antimicrobial agent are also provided.
    Type: Application
    Filed: August 16, 2011
    Publication date: December 8, 2011
    Applicant: TRUSTEES OF TUFTS COLLEGE
    Inventors: Margret OETHINGER, Stuart B. LEVY
  • Publication number: 20110274651
    Abstract: Compositions and methods for treating or preventing infectious diseases, and inhibiting the ability of microbes to travel within mammalian cells, and inhibiting microbial replication, are disclosed. The compositions include various noscapine analogs, which are capable of blocking the movement of viruses and other microbes within mammalian and other cells by inhibiting the cytoplasmic transport mechanisms within the cells. The compositions described herein include an effective amount of the noscapine analogues described herein, along with a pharmaceutically acceptable carrier or excipient. The compositions can also include one or more additional antimicrobial compounds.
    Type: Application
    Filed: September 4, 2009
    Publication date: November 10, 2011
    Applicant: Emory University
    Inventors: Cory Acuff, Daniel Kalman
  • Publication number: 20110224186
    Abstract: Carbacephem ?-lactam antibiotics having the following chemical structure (I) are disclosed: including stereoisomers, pharmaceutically acceptable salts, esters and prodrugs thereof, wherein Ar2, X, R1 and R2 are as defined herein. The compounds are useful for the treatment of bacterial infections, in particular those caused by methicillin-resistant Staphylococcus spp.
    Type: Application
    Filed: March 10, 2011
    Publication date: September 15, 2011
    Applicant: Achaogen, Inc.
    Inventors: Allan Scott Wagman, Heinz Ernst Moser
  • Publication number: 20110082129
    Abstract: The present invention provides novel organic compounds of Formula I: methods of use, and pharmaceutical compositions thereof.
    Type: Application
    Filed: June 25, 2009
    Publication date: April 7, 2011
    Inventors: Christopher Adams, Qi-Ying Hu, Leslie Wighton McQuire, Julien Papillon
  • Publication number: 20100267686
    Abstract: Carbacephem ?-lactam antibiotics having the following chemical structures (I) and (II) are disclosed: including stereoisomers, pharmaceutically acceptable salts, esters and prodrugs thereof, wherein Ar2, R1, R2 and R3 are as defined herein. The compounds are useful for the treatment of bacterial infections, in particular those caused by methicillin-resistant Staphylococcus spp.
    Type: Application
    Filed: April 21, 2010
    Publication date: October 21, 2010
    Applicant: Achaogen, Inc.
    Inventors: Allan S. Wagman, Heinz E. Moser
  • Publication number: 20100016276
    Abstract: Compositions and methods for the rapid and sensitive detection of a carbapenemase in a sample is provided. The compositions include novel primer and probe compositions for use in detecting the presence of this enzyme in a sample, particularly using PCR methods. These primers and probe sets can be used in amplification methods (such as PCR, particularly quantitative PCR) and packaged into kits for use in amplification methods for the purpose of detecting carbapenemase in a test sample, particularly a patient sample, particularly a direct sample. Thus, in one embodiment, the present invention provides for novel oligonucleotide primers set forth in SEQ ID NOs:1, 2, 4, 5, 7, 8, 14, 15, 17, 18, and 20, and the novel oligonucleotide probe sequences set forth in SEQ ID NOs:3, 6, 9, 16, and 19. These sequences can be used in a method of detecting carbapenemase in a sample.
    Type: Application
    Filed: April 7, 2008
    Publication date: January 21, 2010
    Applicant: Becton, Dickinson and Company
    Inventors: Craig C. Whiteford, Charles Yu
  • Publication number: 20090082326
    Abstract: The present invention relates to new dosage forms of cephem compounds, useful for the treatment of bacterial infections. The dosage forms are stable, exhibit enhanced solubility, and are particularly well suited for, e.g., parenteral administration.
    Type: Application
    Filed: September 19, 2008
    Publication date: March 26, 2009
    Applicant: Forest Laboratories Holdings Limited
    Inventors: Mahendra Dedhiya, Yigong Ge
  • Patent number: 7109190
    Abstract: The present invention relates to carbocephem ?-lactam antibiotics having the chemical structure: wherein the compounds are useful for the treatment of bacterial infections, in particular those caused by methicillin-resistant Staphylococcus spp.
    Type: Grant
    Filed: April 27, 2004
    Date of Patent: September 19, 2006
    Assignee: Trine Pharmaceuticals, Inc.
    Inventors: Tomasz W. Glinka, Scott J. Hecker
  • Patent number: 6602864
    Abstract: The compounds of formula I herein exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, which are for treating a patient suffering from, or subject to, physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.
    Type: Grant
    Filed: June 3, 1998
    Date of Patent: August 5, 2003
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Yong Mi Choi-Sledeski, Henry W. Pauls, Jeffrey N. Barton, William R. Ewing, Daniel M. Green, Michael R. Becker, Yong Gong
  • Patent number: 6514962
    Abstract: Stabilized preparations which contain a &bgr;-lactam antibiotic having an esterified carboxyl group attached directly to the mother nucleus, an oil and a phosphate.
    Type: Grant
    Filed: February 5, 2001
    Date of Patent: February 4, 2003
    Assignee: Takeda Schering-Plough Animal Health K.K.
    Inventors: Hatsuo Shibatani, Tomoyasu Nakamura
  • Publication number: 20020183305
    Abstract: The present invention provides compositions, therapeutic combinations and methods including: (a) at least one of nicotinic acid or derivatives thereof; and (b) at least one substituted azetidinone or substituted &bgr;-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols.
    Type: Application
    Filed: January 25, 2002
    Publication date: December 5, 2002
    Applicant: Schering Corporation
    Inventors: Harry R. Davis, Teddy Kosoglou
  • Publication number: 20010041739
    Abstract: This invention relates to a method for the prophylaxis of or reducing the severity of post-viral bacterial infection by administering a PDE 4-specific inhibitor prior to or during the course of a viral infection or thereafter during the course of the bacterial infection.
    Type: Application
    Filed: February 8, 2001
    Publication date: November 15, 2001
    Inventors: Peter L. DeMarsh, Susan B. Dillon, Gary Woodnutt
  • Patent number: 6174877
    Abstract: A cephem compound of the formula: wherein R1 stands for an optionally substituted lower alkyl group, R2 stands for H or a lower alkyl group, R3 stands for H, an optionally substituted hydrocarbon group, cyano group, a lower alkyloxy group or a lower alkylthio group, and the ring A stands for an optionally substituted non-quaternarized nitrogen-containing heterocyclic ring, provided that, when A is unsubstituted 2-pyridyl group, R3 stands for a group other than hydrogen, or their esters or salts, has excellent antibacterial activities, oral absorbability and stability, and is useful as an antibacterial agent.
    Type: Grant
    Filed: July 10, 1998
    Date of Patent: January 16, 2001
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Yukio Ishibashi, Shinichi Imamura, Tetsuo Miwa